NTLA
NASD Intellia Therapeutics, Inc.$12.17 ↑ +0.11 (+0.91%) Trading Up from the previous close of $12.06
- YTD change
- +35.37%
- vs 20-day SMA
- +0.34%
- vs 200-day SMA
- -5.09%
Price ranges
Price & Performance
-1.21 (-9.12%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 94.0% away from all-time highs of $202.73
- NTLA is up 35% since the beginning of the year
- NTLA is down 35% over the past 12 months
- NTLA is down 4% over the past 1 month
- 35% of all NTLA investors are betting against NTLA
NTLA reads neutral: price sits above one of the two key moving averages, the 12-month move is -35.7%.
- Previous minute
- +$0.00
- Last hour
- +$0.13
- Last 5 days
- -1.30%
- vs 8-day SMA
- +0.72%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
